Victory Capital Management Inc. Has $1.44 Million Position in ADMA Biologics, Inc. (NASDAQ:ADMA)

Victory Capital Management Inc. lessened its holdings in ADMA Biologics, Inc. (NASDAQ:ADMA) by 14.4% in the 3rd quarter, HoldingsChannel.com reports. The firm owned 71,946 shares of the biotechnology company’s stock after selling 12,100 shares during the quarter. Victory Capital Management Inc.’s holdings in ADMA Biologics were worth $1,438,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in ADMA. D. E. Shaw & Co. Inc. raised its holdings in shares of ADMA Biologics by 26.8% in the 2nd quarter. D. E. Shaw & Co. Inc. now owns 6,824,517 shares of the biotechnology company’s stock worth $76,298,000 after buying an additional 1,442,799 shares in the last quarter. Assenagon Asset Management S.A. lifted its holdings in shares of ADMA Biologics by 2.7% during the third quarter. Assenagon Asset Management S.A. now owns 3,474,455 shares of the biotechnology company’s stock valued at $69,454,000 after acquiring an additional 92,281 shares during the period. Driehaus Capital Management LLC boosted its stake in shares of ADMA Biologics by 17.3% in the 2nd quarter. Driehaus Capital Management LLC now owns 3,028,667 shares of the biotechnology company’s stock valued at $33,860,000 after purchasing an additional 447,743 shares in the last quarter. Renaissance Technologies LLC grew its holdings in shares of ADMA Biologics by 28.7% in the 2nd quarter. Renaissance Technologies LLC now owns 2,582,135 shares of the biotechnology company’s stock worth $28,868,000 after purchasing an additional 575,100 shares during the last quarter. Finally, Federated Hermes Inc. increased its position in shares of ADMA Biologics by 15.5% during the 2nd quarter. Federated Hermes Inc. now owns 1,969,811 shares of the biotechnology company’s stock worth $22,022,000 after purchasing an additional 263,677 shares in the last quarter. Institutional investors own 75.68% of the company’s stock.

ADMA Biologics Stock Up 1.4 %

Shares of NASDAQ:ADMA opened at $21.47 on Tuesday. The company has a quick ratio of 3.26, a current ratio of 7.09 and a debt-to-equity ratio of 0.48. The firm has a market cap of $5.08 billion, a P/E ratio of 75.64 and a beta of 0.64. ADMA Biologics, Inc. has a 12 month low of $3.60 and a 12 month high of $23.64. The company’s 50-day moving average price is $18.86 and its two-hundred day moving average price is $14.95.

ADMA Biologics (NASDAQ:ADMA) last released its quarterly earnings results on Thursday, November 7th. The biotechnology company reported $0.15 EPS for the quarter, beating the consensus estimate of $0.13 by $0.02. ADMA Biologics had a net margin of 17.80% and a return on equity of 53.20%. The business had revenue of $119.84 million for the quarter, compared to analysts’ expectations of $107.25 million. During the same period in the prior year, the firm earned $0.01 earnings per share. As a group, research analysts forecast that ADMA Biologics, Inc. will post 0.52 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research firms have commented on ADMA. Cantor Fitzgerald restated an “overweight” rating and issued a $20.00 price target on shares of ADMA Biologics in a research report on Friday, September 20th. HC Wainwright boosted their target price on ADMA Biologics from $18.00 to $26.00 and gave the stock a “buy” rating in a report on Friday, November 8th. Finally, Raymond James raised their price target on ADMA Biologics from $18.00 to $25.00 and gave the company a “strong-buy” rating in a report on Friday, November 8th.

Insider Activity

In related news, CFO Brad L. Tade sold 15,000 shares of ADMA Biologics stock in a transaction on Friday, November 22nd. The stock was sold at an average price of $21.15, for a total transaction of $317,250.00. Following the completion of the sale, the chief financial officer now directly owns 199,433 shares of the company’s stock, valued at $4,218,007.95. The trade was a 7.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Jerrold B. Grossman sold 136,861 shares of the stock in a transaction dated Thursday, August 29th. The shares were sold at an average price of $17.27, for a total value of $2,363,589.47. Following the completion of the transaction, the director now directly owns 467,305 shares in the company, valued at $8,070,357.35. The trade was a 22.65 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 185,011 shares of company stock valued at $3,255,204 over the last 90 days. 3.70% of the stock is owned by company insiders.

ADMA Biologics Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.